Although its original FDA-approved brand for childhood growth deficiency was discontinued in 2008 due to business reasons, it was not because of safety concerns
The prescription peptides semaglutide, liraglutide, and tirzepatide are generally intended for people with a body mass index (BMI) of 30 or higher , or a BMI of 27 or higher with weight-related health conditions such as type 2 diabetes, high blood pressure, or sleep apnea (FDA Wegovy prescribing information)
It is estimated that up to 40% of the population carries at least one variant of the MTHFR gene (such as the C677T polymorphism), which significantly reduces the enzyme's ability to convert dietary folate into its active form, L-5-MTHF
We're here to be your partner in that journey, providing the tools and expertise you need to push the boundaries of scientific understanding
Medical College of Virginia